Apellis Pharmaceuticals Inc. (APLS) saw its stock price tumble 5.23% in pre-market trading on Wednesday following the release of its first-quarter 2025 financial results. The biopharmaceutical company's earnings report revealed significant losses despite notable product revenue, raising concerns among investors about its path to profitability.

According to the company's Q1 2025 report, Apellis generated product revenue of $149.9 million. However, this was overshadowed by operating expenses of $250.125 million, resulting in an operating loss of $83.328 million. The company's net loss for the quarter stood at $92.225 million, translating to a basic earnings per share (EPS) of -$0.74.

The substantial gap between revenue and expenses appears to be the primary driver of the stock's pre-market decline. Investors may be expressing concern over the company's high burn rate and the challenges it faces in achieving profitability. As Apellis continues to invest heavily in its operations, likely for research and development of its pharmaceutical products, the market seems to be questioning the timeline for these investments to translate into sustainable earnings.